Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $50.61 and last traded at $52.05, with a volume of 920758 shares changing hands. The stock had previously closed at $54.43.
Analyst Ratings Changes
SRPT has been the subject of a number of recent research reports. Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their target price for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Morgan Stanley lowered their price objective on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research note on Friday. Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a research report on Friday. They set an "overweight" rating and a $115.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Finally, Needham & Company LLC dropped their price target on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research note on Thursday, April 3rd. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $161.83.
View Our Latest Analysis on Sarepta Therapeutics
Sarepta Therapeutics Trading Up 1.4 %
The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock's 50 day moving average is $88.11 and its 200-day moving average is $110.20. The company has a market cap of $4.95 billion, a PE ratio of 40.82 and a beta of 0.93.
Insider Activity at Sarepta Therapeutics
In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock worth $2,607,000 after acquiring an additional 39,991 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock valued at $571,000 after purchasing an additional 218 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Sarepta Therapeutics by 11.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company's stock worth $36,392,000 after purchasing an additional 31,098 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $5,713,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Stories
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
